Localized prostate cancer: No OS benefit beyond 15 years with added short-term ADT

Key clinical point: In a long-term follow-up, adding short-term androgen deprivation therapy (ADT) to radiotherapy in patients with localized prostate cancer does not show overall survival (OS) benefit after 15 years.

Major finding: The OS curves of the 2 groups converge at 15 years. In the radiotherapy-alone vs combination treatment group, the OS rate at 18 years was 23% vs 23% (hazard ratio, 0.94; P =.94).

Study details: A randomized, phase 3 NRG/RTOG 9408 study of 2,028 patients with localized prostate cancer and prostate-specific antigen of ≤20 ng/mL who were randomly assigned to radiotherapy alone or radiotherapy plus short-term ADT.

Disclosures: This work was supported by National Cancer Institute. The authors performed advisory/consulting roles, received personal fees/grants and/or salary/stipend, chaired committees, and/or were employed by/owned stocks in pharmaceutical companies.

Source: Jones CU et al. Int J Radiat Oncol Biol Phys. 2021 Aug 31. doi: 10.1016/j.ijrobp.2021.08.031.

Key clinical point: In a long-term follow-up, adding short-term androgen deprivation therapy (ADT) to radiotherapy in patients with localized prostate cancer does not show overall survival (OS) benefit after 15 years.

Major finding: The OS curves of the 2 groups converge at 15 years. In the radiotherapy-alone vs combination treatment group, the OS rate at 18 years was 23% vs 23% (hazard ratio, 0.94; P =.94).

Study details: A randomized, phase 3 NRG/RTOG 9408 study of 2,028 patients with localized prostate cancer and prostate-specific antigen of ≤20 ng/mL who were randomly assigned to radiotherapy alone or radiotherapy plus short-term ADT.

Disclosures: This work was supported by National Cancer Institute. The authors performed advisory/consulting roles, received personal fees/grants and/or salary/stipend, chaired committees, and/or were employed by/owned stocks in pharmaceutical companies.

Source: Jones CU et al. Int J Radiat Oncol Biol Phys. 2021 Aug 31. doi: 10.1016/j.ijrobp.2021.08.031.

Key clinical point: In a long-term follow-up, adding short-term androgen deprivation therapy (ADT) to radiotherapy in patients with localized prostate cancer does not show overall survival (OS) benefit after 15 years.

Major finding: The OS curves of the 2 groups converge at 15 years. In the radiotherapy-alone vs combination treatment group, the OS rate at 18 years was 23% vs 23% (hazard ratio, 0.94; P =.94).

Study details: A randomized, phase 3 NRG/RTOG 9408 study of 2,028 patients with localized prostate cancer and prostate-specific antigen of ≤20 ng/mL who were randomly assigned to radiotherapy alone or radiotherapy plus short-term ADT.

Disclosures: This work was supported by National Cancer Institute. The authors performed advisory/consulting roles, received personal fees/grants and/or salary/stipend, chaired committees, and/or were employed by/owned stocks in pharmaceutical companies.

Source: Jones CU et al. Int J Radiat Oncol Biol Phys. 2021 Aug 31. doi: 10.1016/j.ijrobp.2021.08.031.